Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
Apple Turns 50: From Garage Startup to AI Crossroads 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
COPENHAGEN, Denmark, July 14, 2017 -- Vilacto Bio Inc. (OTC QB:VIBI), is pleased to announce that the upgrade of its production facility was completed this week. The upgrade has been in process the last 6 weeks and has included an additional storage container, improved mixing machines and upscale filtration unit. The upgrade allows Vilact Bio Inc to increase its production of its Lactoactive® molecule and output with an estimated 300% which the company anticipates will be needed as a part of the new range of products that is being launched this fall.
“This is another important step in our evolution as a skin care and Biotech Company and we are pleased to make this announcement," states Gert Anderson, CEO of Vilacto Bio Inc.
About Vilacto Bio Inc.:
Vilacto Bio Inc. (OTC QB:VIBI), is a biotech company that has developed the now fully patented Lactoactive® (Lactoactive molecule) that in numerous studies has demonstrated above average effect treating conditions such as inflammatory diseases, diabetes, psoriasis, skin aging, and skin issues in different levels. We aim to further develop our Lactoactive® molecule for the purpose of increasing the quality of our retail and medical skin cream products as well as licensing out our Lactoactive® molecule for the pharmaceutical industry.
Find out about Vilact on instagram https://www.instagram.com/vilact_com/ and facebook https://da-dk.facebook.com/skincare.vilact/.
Vilacto Bio Inc. The Seagram Building 375 Park Avenue, Suite 2607 New York City, NY 10152 Gert Andersen Phone: +1 646-893-7895 [email protected] www.vilactobio.com Source: Vilacto Bio Inc.
